Previous Article | Next Article ![]()
Journal of Virology, August 2003, p. 8570-8576, Vol. 77, No. 15
0022-538X/03/$08.00+0 DOI: 10.1128/JVI.77.15.8570-8576.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Armed Forces Research Institute of Medical Sciences, Bangkok 10400,1 Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand,3 The Henry M. Jackson Foundation,2 Walter Reed Army Institute of Research, Rockville, Maryland 208504
Received 13 January 2003/ Accepted 8 May 2003
A number of human immunodeficiency virus type 1 (HIV-1) non-B-subtype products have been developed for present or future vaccine trials; in Thailand, several studies using subtype B and/or CRF01_AE vaccines have been conducted. To better characterize the biologic properties of these subtypes, 70 HIV-1 subtype B and E isolates were phenotyped as syncytium-inducing (SI) or non-syncytium-inducing (NSI) isolates and assessed for sensitivity to neutralizing antibody (NAb). A significantly higher number of NSI subtype E viruses were neutralization sensitive than SI subtype E viruses (P = 0.009), while no association between viral phenotype and sensitivity to NAb was observed for subtype B (P = 0.856), suggesting a difference in the neutralization patterns of subtypes B and E. Strikingly, concurrent CD4 T-cell numbers were significantly lower for subtype E-infected patients whose isolates were more resistant to NAb, both for the overall study group (P < 0.001) as well as for the 22 patients with NSI isolates (P = 0.013). Characterization of the evolution of biologic properties of both B and non-B HIV-1 subtypes will provide a clearer understanding of the repertoire of antibodies that must be elicited for a vaccine to be effective against all phenotypes and subtypes.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»